Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28410513 | 1.00 | MAP2K1 (0.41) | MAP2K1MAP2K2FLT1HDAC3HDAC1 | |
| SCHEMBL29536827 | 0.90 | MAP2K1 (0.43) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL28406155 | 0.90 | MAP2K1 (0.43) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL20564882 | 0.88 | MAP2K1 (0.49) | MAP2K1MAP2K2FLT1HDAC3HDAC1 | |
| SCHEMBL30035019 | 0.88 | MAP2K1 (0.49) | MAP2K1MAP2K2FLT1HDAC3HDAC1 | |
| SCHEMBL20564894 | 0.84 | MAP2K1 (0.43) | MAP2K1MAP2K2FLT1HDAC3HDAC1 | |
| SCHEMBL20565254 | 0.83 | MAP2K1 (0.40) | MAP2K1MAP2K2FLT1CISD2 | |
| SCHEMBL30035117 | 0.83 | MAP2K1 (0.40) | MAP2K1MAP2K2FLT1CISD2 | |
| SCHEMBL29536816 | 0.83 | MAP2K1 (0.40) | MAP2K1MAP2K2FLT1CISD2 | |
| SCHEMBL20565325 | 0.81 | MAP2K1 (0.56) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-113645964-B | Arylaniline and heteroaryl aniline compounds for fetal treatment | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-113660931-B | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885FLT1 2710/4885 |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NCOA3, TYR, CYP3A43 | MAP2K1 2772/4885MAP2K2 2465/4885FLT1 1550/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885FLT1 2396/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MAP2K1 3307/4885MAP2K2 3471/4885FLT1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.